Atopic dermatitis‐like graft‐versus‐host disease treated with dupilumab. Issue 2 (21st October 2022)

• Record Type: Journal Article
• Authors: Larijani, Mary; Zarowin, Diana; Wohlschlaeger, Anne; Perman, Marissa J.; Treat, James R.
• Is Part Of: Pediatric dermatology. Volume 40:Issue 2(2023)
• Page Start: 320
• Page End: 322
• Publication Date: 2022-10-21
• Subjects: atopic dermatitis -- skin signs of systemic disease -- therapy‐systemic; Pediatric dermatology -- Periodicals; Children -- Diseases -- Periodicals; 618.925
• DOI: 10.1111/pde.15146
• Languages: English
• ISSNs: 0736-8046

Abstract

Abstract: The mainstay of treatment for atopic dermatitis (AD)‐like graft‐versus‐host disease (GVHD) in both pediatric and adult patients includes oral corticosteroids with or without other systemic immunosuppressive therapies. To our knowledge, we report the first case series of dupilumab in the treatment of AD‐like GVHD in a pediatric cohort of four patients, where we observed clinical improvement of GVHD as well as a reduction in itch in 3/4 (75%) patients. Our findings suggest that dupilumab is not only effective in treating AD‐like GVHD, but also reduces systemic immunosuppression in the pediatric transplant population. The ability to reduce the length and amount of immunosuppression as well as improve quality of life suggest that dupilumab may serve as a safe and effective therapeutic option in our transplant population with GVHD.